Literature DB >> 12855568

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.

Takahiro Fukuda1, Robert C Hackman, Katherine A Guthrie, Brenda M Sandmaier, Michael Boeckh, Michael B Maris, David G Maloney, H Joachim Deeg, Paul J Martin, Rainer F Storb, David K Madtes.   

Abstract

Idiopathic pneumonia syndrome (IPS) is a significant noninfectious complication of hematopoietic stem cell transplantation (HSCT). We compared the incidences and outcomes of IPS among patients who underwent allogeneic HSCT after nonmyeloablative (n = 183) compared with conventional (n = 917) conditioning between December 1997 and December 2001. Patients given nonmyeloablative conditioning were older than those given conventional conditioning (median ages, 53 vs 41 years; P =.001). The cumulative incidence of IPS was significantly lower at 120 days after nonmyeloablative conditioning than conventional conditioning (2.2% vs 8.4%; P =.003). In addition, greater patient age (older than 40 years), diagnosis of acute leukemia or myelodys-plastic syndrome, and severe acute graft-versus-host disease were associated with significantly increased risks for IPS. Among older patients (older than 40 years) given conventional conditioning, high-dose total body irradiation (TBI) was associated with an increased risk for IPS than were non-TBI-based regimens (16% vs 5.8%; P =.001). IPS occurred early after transplantation, progressed rapidly, and was associated with a high mortality rate (75%) despite aggressive support. Initiation of mechanical ventilation and the presence of renal insufficiency at IPS onset were associated with increased risks for death after IPS. These findings support the concept that lung damage from the conditioning regimen plays a crucial role in the development of IPS after HSCT.

Entities:  

Mesh:

Year:  2003        PMID: 12855568     DOI: 10.1182/blood-2003-05-1597

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.

Authors:  Brenda M Sandmaier; Stephen Mackinnon; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

2.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 3.  Allogeneic hematopoietic cell transplantation: the state of the art.

Authors:  Boglarka Gyurkocza; Andrew Rezvani; Rainer F Storb
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

4.  Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

Authors:  J W Chien; M Sakai; T A Gooley; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-06-29       Impact factor: 5.483

Review 5.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

Review 6.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.

Authors:  Smita Bhatia
Journal:  Expert Rev Hematol       Date:  2011-08       Impact factor: 2.929

Review 7.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

8.  Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies.

Authors:  Sachiko Seo; Christian Renaud; Jane M Kuypers; Charles Y Chiu; Meei-Li Huang; Erik Samayoa; Hu Xie; Guixia Yu; Cynthia E Fisher; Ted A Gooley; Steven Miller; Robert C Hackman; David Myerson; Ruth H Sedlak; Yae-Jean Kim; Takahiro Fukuda; David N Fredricks; David K Madtes; Keith R Jerome; Michael Boeckh
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

9.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

10.  A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Authors:  Gerhard C Hildebrandt; Krystyna M Olkiewicz; Leigh Corrion; Shawn G Clouthier; Elizabeth M Pierce; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.